324 related articles for article (PubMed ID: 27012985)
1. Nivolumab-induced thyroid dysfunction.
Tanaka R; Fujisawa Y; Maruyama H; Nakamura Y; Yoshino K; Ohtsuka M; Fujimoto M
Jpn J Clin Oncol; 2016 Jun; 46(6):575-9. PubMed ID: 27012985
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
4. A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
Yuki A; Takenouchi T; Takatsuka S; Ishiguro T
Melanoma Res; 2017 Dec; 27(6):635-637. PubMed ID: 28872489
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer.
Badovinac S; Korsic M; Zarkovic K; Mursic D; Roglic M; Jakopovic M; Samarzija M
Immunotherapy; 2018 Mar; 10(6):427-431. PubMed ID: 29562858
[TBL] [Abstract][Full Text] [Related]
8. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
Okiyama N; Tanaka R
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
[TBL] [Abstract][Full Text] [Related]
9. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
10. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.
Maekura T; Naito M; Tahara M; Ikegami N; Kimura Y; Sonobe S; Kobayashi T; Tsuji T; Minomo S; Tamiya A; Atagi S
In Vivo; 2017; 31(5):1035-1039. PubMed ID: 28882978
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab induced myxedema crisis.
Khan U; Rizvi H; Sano D; Chiu J; Hadid T
J Immunother Cancer; 2017; 5():13. PubMed ID: 28239466
[TBL] [Abstract][Full Text] [Related]
12. [Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].
Qi L; Mo HN; Chen XL; Wang X; Wu DW; Lan B; Li Q; Wang XY; Xu JP; Yang Q; Xu BH; Huang J
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):772-775. PubMed ID: 30392342
[No Abstract] [Full Text] [Related]
13. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
14. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
[TBL] [Abstract][Full Text] [Related]
15. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
16. [Nivolumab-induced hypothyroidism: A case report].
Lin C; Guo Z; Mo Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Feb; 44(2):222-224. PubMed ID: 30837393
[TBL] [Abstract][Full Text] [Related]
17. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.
Zeng MF; Chen LL; Ye HY; Gong W; Zhou LN; Li YM; Zhao XL
Medicine (Baltimore); 2017 Nov; 96(44):e8426. PubMed ID: 29095280
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
Edmondson LA; Smith LV; Mallik A
J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
Zhang X; Wu Y; Lv J; Li X; Ma L; Nong J; Zhang H; Qin N; Zhang Q; Shi G; Yang X; Wang J; Zhang S
Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
[TBL] [Abstract][Full Text] [Related]
20. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
